Australia, Sept. 29 -- Ocugen Inc., owns the trademark (2629734) for 'LYTSTARIQ' till Feb. 23, 2036.
Status: registered:
Registered/protected
Class: 5 [Gene therapy products, namely, genetically engineered tissues for transplant purposes; pharmaceutical preparations for gene therapy for the treatment of ocular disease, such as Stargardt Disease; pharmaceutical preparations for gene therapy for the treatment of Stargardt Disease]
Type of Mark: Word
Date of Acceptance: Feb. 25
Registration Advertised: Sept. 28
For further details contact LAMINAR IP Pty. Ltd. .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2629734.
Disclaimer: Curated by HT Syndication.
